Cerus Aktie - Fundamentalanalyse - Dividendenrendite KGV

Cerus (ISIN: US1570851014, WKN: 905249) Kursdatum: 19.06.2018 Kurs: 7,010 USD
Beschreibung Daten
Symbol CERS
Marktkapitalisierung 758.629.184,00 USD
Land Vereinigte Staaten von Amerika
Indizes NASDAQ Comp.
Sektor Gesundheitswesen
Rohdaten nach US GAAP in Millionen USD
Aktiensplits
Internet www.cerus.com
Letztes Bilanz Update 10.03.2018

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 19.06.2018
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
-14,43 -14,52 0,00% -61,69 39,64 -12,52 14,78 19,48

Firmenbeschreibung

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company\'s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

Die Finanzoo GmbH übernimmt keine Haftung für die Richtigkeit der Angaben! Alle Angaben sind ohne Gewähr. Quellen: www.bundesanzeiger.de, www.sec.gov, www.cerus.com